The Portnoy Law Firm has announced a class action lawsuit on behalf of Soleno Therapeutics investors who purchased securities between March 6, 2025 and November 4, 2025. The lawsuit alleges that Soleno concealed significant safety risks related to its lead drug DCCR, including excess fluid retention issues discovered in Phase 3 trials. The stock ...

A class action lawsuit has been filed against Soleno Therapeutics for allegedly making false statements and concealing safety concerns regarding its DCCR drug candidate for Prader-Willi syndrome treatment. The complaint alleges the company downplayed evidence of fluid retention issues in clinical trials and misrepresented the drug's commercial vi...

A securities class action lawsuit has been filed against Soleno Therapeutics regarding alleged false and misleading statements about safety concerns with its DCCR drug candidate for Prader-Willi syndrome. The lawsuit claims the company downplayed evidence of fluid retention issues in clinical trials and concealed materially greater safety risks, ...

A class action lawsuit has been filed against Soleno Therapeutics, Inc. alleging that the company failed to disclose significant safety concerns related to its DCCR drug candidate, including excess fluid retention issues in clinical trials. The lawsuit claims these undisclosed risks materially reduced the drug's commercial viability and posed gre...

A class action lawsuit has been filed against Atara Biotherapeutics alleging securities fraud. The complaint claims the company made false statements about manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. Investors who purchased Atara securities between May 20, 2024 and January 9, ...